CD274 and melanoma: In addition, immunotherapy targeting the PD1/PDL1 axis has been receiving approval since 2014 for second-line or first-line therapies for an increasing number of malignancies, including melanoma, lymphoma, NSCLC, renal cell cancer, head and neck squamous cell cancer, bladder cancer, liver cancer, esophagogastric junction cancer, and micro-satellite unstable cancer of any origin [153,154].